Followers | 91 |
Posts | 3296 |
Boards Moderated | 0 |
Alias Born | 10/18/2010 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, June 04, 2020 10:09:05 PM
In addition to the headline grabbing remdesivir, Gilead is the biggest player in the HIV space, manufacturing what could become the best-selling HIV drug ever, Biktarvy.
Having said that, Gilead has been expanding, and through a series of M&As, building an increasingly strong oncology portfolio. Following the addition of Kite in 2018 and the more recent acquisition of cancer-focused biotech Forty Seven, Gilead has just inked a deal with immuno-oncology player Arcus Biosciences. They have agreed to a 10-year partnership to develop next-generation cancer immunotherapies. Arcus will bring a number of immuno-oncology assets to the table, including a PD-1, anti-TIGIT, CD73 inhibitor, and a dual A2a/A2b antagonist, and in return, will receive $175 million upfront, a $200 million equity investment and R&D funding to the tune of $1.6 billion.
Gilead has a similarly structured, though larger, deal in place with Galapagos. In total, Gilead invested $5.1 billion in the Belgian-Dutch biotech last year. The two are working together on rheumatoid arthritis treatment, filgotinib, which is currently awaiting U.S. and European regulatory approval.
Weighing in for Maxim Group, analyst Jason McCarthy believes Gilead’s ever-growing portfolio will present the large-cap with fresh opportunities.
The 5-star analyst said, “With near-complete dominance in HIV and a steadily declining Hep-C franchise, inflammation and oncology have been positioned as the next growth areas for Gilead. Deals like the Galapagos and Arcus partnerships represent an attractive structure for Gilead, granting them access to deep therapeutic candidate pipelines while mitigating risk by not acquiring the companies outright. More 'bolt-ons' like Galapagos and Arcus, or full acquisitions? We'll see as Gilead continues its transformation.”
Waiting to see how things play out, McCarthy maintains a Hold recommendation on Gilead. He also has not set a price target
Recent GILD News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/29/2024 07:23:50 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/28/2024 08:18:35 PM
- Gilead Sciences to Present at Upcoming Investor Conferences • Business Wire • 08/21/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 06:23:44 PM
- Gilead’s Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA • Business Wire • 08/14/2024 05:59:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/13/2024 08:27:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/12/2024 08:22:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 09:17:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:06:06 PM
- Gilead Sciences Announces Second Quarter 2024 Financial Results • Business Wire • 08/08/2024 08:02:00 PM
- U.S. Index Futures Drop, Signaling Ongoing Market Volatility; Oil Prices Stall • IH Market News • 08/08/2024 09:55:44 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/26/2024 09:28:51 PM
- Gilead Sciences to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024 • Business Wire • 07/25/2024 08:05:00 PM
- Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline • Business Wire • 07/25/2024 01:15:00 PM
- Full Efficacy and Safety Results for Gilead Investigational Twice-Yearly Lenacapavir for HIV Prevention Presented at AIDS 2024 • Business Wire • 07/24/2024 08:30:00 AM
- Gilead and the Elton John AIDS Foundation Announce Additional Five Years of RADIAN Partnership to Help Address the Growing HIV Crisis in Eastern Europe and Central Asia • Business Wire • 07/22/2024 08:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/17/2024 01:01:01 PM
- Chief Medical Officer Merdad Parsey to Leave Gilead Early 2025 • Business Wire • 07/17/2024 12:50:00 PM
- Gilead to Highlight Landmark Progress in Research Across HIV Prevention, Treatment and Cure Programs at AIDS 2024 • Business Wire • 07/16/2024 12:30:00 PM
- EFFICACITÉ DE 100 % ET SUPÉRIORITÉ AVÉRÉES DU LÉNACAPAVIR DE GILEAD UTILISÉ DEUX FOIS PAR AN PAR RAPPORT À TRUVADA (MD) UNE FOIS PAR JOUR POUR LA PRÉVENTION DU VIH • PR Newswire (Canada) • 06/26/2024 02:45:00 PM
- Honeywell Acquires CAES Systems for $1.9 Billion, Sarepta Therapeutics Surges 34%, Gilead Continues Gains • IH Market News • 06/21/2024 12:00:38 PM
- Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention • Business Wire • 06/20/2024 12:51:00 PM
- Goldman Sachs Raises S&P 500 Forecast for 2024; Disney Secures Deadpool & Wolverine in Chinese Cinemas, and More • IH Market News • 06/17/2024 10:49:12 AM
- New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment • Business Wire • 06/14/2024 07:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 11:25:27 PM
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM